Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03240133
Recruitment Status : Completed
First Posted : August 4, 2017
Results First Posted : April 1, 2021
Last Update Posted : April 1, 2021
Information provided by (Responsible Party):
BioCryst Pharmaceuticals

Brief Summary:
This 3-part study will evaluate the efficacy and safety of an oral kallikrein inhibitor, BCX7353, in the treatment angioedema attacks in subjects with Type I or II hereditary angioedema (HAE). In each study part, subjects will treat 3 attacks with BCX7353 (2 attacks) or placebo (1 attack), in a randomly allocated order. In Part 1, the dose of 750mg will be assessed relative to placebo in up to 36 patients. If this is shown to be effective, then a further 12 patients will be enrolled at a 500mg dose (Part 1), followed by a further 12 (if efficacy still shown) at a dose of 250mg (Part 3) to determine the minimum effective dose of BCX7353 compared to placebo for treating HAE attacks. Efficacy will be determined by subject diary entries completed at pre-defined times post-dose.

Condition or disease Intervention/treatment Phase
Hereditary Angioedema (HAE) Drug: BCX7353 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 58 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Study to Evaluate the Efficacy, Safety and Tolerability of Single Doses of BCX7353 as an Acute Attack Treatment in Subjects With Hereditary Angioedema
Actual Study Start Date : July 31, 2017
Actual Primary Completion Date : January 29, 2019
Actual Study Completion Date : January 29, 2019

Arm Intervention/treatment
Experimental: Part1: BCX7353 750 mg Drug: BCX7353
oral liquid formulation

Experimental: Part 2: BCX7353 500 mg Drug: BCX7353
oral liquid formulation

Experimental: Part 3: BCX7353 250 mg Drug: BCX7353
oral liquid formulation

Placebo Comparator: Parts 1, 2 and 3: placebo Drug: Placebo
oral liquid formulation to match BCX7353

Primary Outcome Measures :
  1. Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score [ Time Frame: Mean composite VAS for HAE attack symptoms severity prior to IMP treatment and 4 hours post-dose ]
    Subjects completed a 3-component VAS on a 100 mm scale for severity of abdominal pain, skin pain and skin swelling associated with the HAE attack, where zero indicated no pain or swelling and 100 mm indicated worst possible pain or swelling. Subjects completed the VAS immediately prior to study drug administration, then at 1, 2, 3, 4, approximately 8 & at 24 hours post-dose. The primary endpoint was the proportion of subject attacks with an improved or stable 3-symptom composite VAS score at 4 hours post dose. The 3-symptom composite was calculated as the average of the VAS scores for abdominal pain, skin pain, and skin swelling. A subject was considered improved or stable if the change from baseline (CFB; time of drug administration) in VAS was ≤ 0.

  2. Percentage of Attacks Treated With Standard of Care Acute Attack Medication (SOC-Rx) Through 24 Hours [ Time Frame: 24 hours ]
    The proportion of attacks for which subjects took SOC-Rx in the 24 hours following treatment with study drug. HAE Rescue Medications included C1-INH (Berinert, Cinryze, Ruconest) and Firazyr/Icatibant.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Able to provide written, informed consent.
  2. A clinical diagnosis of hereditary angioedema Type 1 or Type 2 as documented at any time in the medical records or at the screening visit.
  3. Access to and ability to use standard of care acute attack treatment for attacks of HAE.
  4. Sexually active women of child-bearing potential and sexually active men must utilize effective contraception.

Exclusion Criteria:

  1. Women who are pregnant or breast-feeding.
  2. Any clinical condition or medical history that would interfere with the subject's safety or ability to participate in the study.
  3. Use of C1INH, androgens or tranexamic acid for prophylaxis of HAE attacks.
  4. History of or current alcohol or drug abuse.
  5. Infection with hepatitis B, hepatitis C or HIV.
  6. Participation in any other investigational drug study currently or within the last 30 days.
  7. Positive drugs of abuse screen (unless as used as medical treatment, e.g., with a prescription).
  8. An immediate family relationship to either Sponsor employees, the Investigator or employees of the study site.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03240133

Layout table for location information
Study Center
Graz, Austria
Study Center
Odense, Denmark
Study Center
Grenoble, France
Study Center
Lille, France
Study Center
Berlin, Germany
Study Center
Frankfurt, Germany
Study Center
Budapest, Hungary
Study Center
Ashkelon, Israel
Study Center
Tel Aviv, Israel
Study Center
Tel HaShomer, Israel
Study Center
Milano, Italy
Study center
Padova, Italy
Study Center
Salerno, Italy
North Macedonia
Study Center
Skopje, North Macedonia
Study Center
Kraków, Poland
Study Center
Târgu-Mureş, Romania
Study Center
Zürich, Switzerland
United Kingdom
Study Center
Birmingham, United Kingdom
Study Center
Bristol, United Kingdom
Study Center
Cambridge, United Kingdom
Study Center
London, United Kingdom
Study Center
Manchester, United Kingdom
Study Center
Plymouth, United Kingdom
Study Center
Southampton, United Kingdom
Sponsors and Collaborators
BioCryst Pharmaceuticals
Layout table for investigator information
Principal Investigator: Hilary Longhurst, MBBS, PhD Barts & The London NHS Trust
  Study Documents (Full-Text)

Documents provided by BioCryst Pharmaceuticals:
Statistical Analysis Plan  [PDF] January 29, 2019
Study Protocol  [PDF] March 16, 2018

Layout table for additonal information
Responsible Party: BioCryst Pharmaceuticals Identifier: NCT03240133    
Other Study ID Numbers: BCX7353-202
First Posted: August 4, 2017    Key Record Dates
Results First Posted: April 1, 2021
Last Update Posted: April 1, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BioCryst Pharmaceuticals:
hereditary angioedema
kallikrein inhibitor
plasma kallikrein
Additional relevant MeSH terms:
Layout table for MeSH terms
Angioedemas, Hereditary
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Immune System Diseases
Hereditary Complement Deficiency Diseases
Primary Immunodeficiency Diseases
Genetic Diseases, Inborn
Immunologic Deficiency Syndromes
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action